Comparison of revised EWGSOP2 criteria of sarcopenia in patients with cancer using different parameters of muscle mass

Ana Paula Trussardi Fayh1,2,3*, Iasmin Matias de Sousa1,2

1 Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil, 2 Postgraduate Program in Nutrition, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil, 3 Postgraduate Program in Physical Education, Health Sciences Center, Federal University of Rio Grande do Norte, Natal, RN, Brazil

* apfayh@yahoo.com.br

Abstract

Calf circumference (CC) has been established as a marker of muscle mass (MM) with good performance for predicting survival in individuals with cancer. The study aims to determine the prevalence of sarcopenia according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria and to evaluate the accuracy of sarcopenia using low CC relative to MM assessment by computed tomography (CT) at third lumbar vertebra level (L3) as a reference. Cross-sectional study with cancer patients aged ≥ 60 years. Data included socio-demographic, clinical and anthropometric variables. MM was assessed by CC and by CT images at the L3. Sarcopenia was diagnosed according to the EWGSOP2 criteria: a) low handgrip strength (HGS) + reduced MM evaluated by CT; and b) low HGS + low CC. Pearson’s correlation, accuracy, sensitivity, specificity, positive predictive and negative predictive value were analyzed. A total of 108 patients were evaluated, age of 70.6 ± 7.4 years (mean ± standard deviation). The prevalence of sarcopenia was of 24.1% (low MM) and 25.9% (low CC). The Kappa test showed a substantial agreement (K = 0.704), 81% sensitivity, and 92% specificity. Although the EWGSOP2 advises that we should use CC measures in the algorithm for sarcopenia when no other MM diagnostic methods are available, the findings allow the use of CC instead of MM by CT in cancer patients.

Introduction

People worldwide are living longer. According to the World Health Organization (WHO), today, the number of people aged 60 years and older will outnumber children younger than 5 years [1]. In Brazil, “older adults” are 60 years of age or older, and it is estimated that this group will represent 18.6% in 2030 and 33.7% in 2060 of the total population [2]. The risk of cancer increases exponentially with age; about 60% of cancers occur in people of 65 years of age or older, and 70% of the deaths caused by cancers occur in this stage [3, 4]. The prevalence of malnutrition in patients with cancer varies according to the type and stage of the tumor, treatment performed, as well as age [5–7]. Chemotherapy and radiation
therapy cause side effects more often and in greater severity to the elderly than to the young, and frequently they can cause loss of muscle mass (MM) [8, 9]. Moreover, older cancer patients usually present loss in physical function and disability, both associated with losses of functional reserve, which, in the presence of chemotherapy, increases the likelihood that these patients will experience toxic side effects [8]. Therefore, elderly patients with cancer are easy to become sarcopenic.

The term “Sarcopenia” has originally been proposed to describe the age-related decrease in MM, today known as primary sarcopenia [10, 11]. The European Working Group on Sarcopenia in Older People (EWGSOP) suggests that sarcopenia should be evaluated through the association between reduced MM and reduced muscle function [12–14]. Since the publication of the revised version of this document (EWGSOP2), both muscle quantity and quality are accepted in the algorithm of sarcopenia [15]. Muscle quality, best described as myosteatosis, as well as the amount of MM (quantity), can be measured by the analysis of computed tomography (CT) images [16–18], a tool usually used for diagnostic of low MM in cancer patients, also known as CT-sarcopenia. However, because of occasionally unavailable technology and equipment, MM assessment remains as a problematic variable to be measured in the clinical practice of cancer patient care and in the identification of sarcopenia in these patients. 

According to the revised version of guidelines of sarcopenia in older people (EWGSOP2), calf circumference (CC) has been presented as a predictor of performance and survival in older people, and may be used as a diagnostic proxy for older adults in contexts where no other MM diagnostic methods are available [15]. However, no studies comparing these two parameters of MM (CC vs CT image) for evaluating the prevalence of sarcopenia estimated by the EWGSOP2 reference in this population were available. Thus, the present study aimed to determine the prevalence of sarcopenia by applying the EWGSOP2 algorithm and evaluating the agreement of sarcopenia based on low CC considering sarcopenia-based CT image (MM) as a reference method in patients with cancer.

Materials and methods

Design and subjects

A cross-sectional study including elderly cancer patients of both genders, aged 60 years or older, in a primary care hospital, Brazil. Patients in all cancer treatment modalities (surgical, chemotherapy, radiotherapy or combined), able to perform evaluations and who had CT images of the abdominal region in the last 30 days were included. Patients with concomitant consumptive diseases (AIDS, non-cancerous liver diseases, tuberculosis), with ascites, edema or amputation, which made it impossible to analyze their CT images or measuring CC, were excluded. The study was approved by the Research Ethics Committee of the Federal University of Rio Grande do Norte (protocol number 73315617.4.0000.5292).

Procedures

The study was conducted between January 2017 and March 2019. All eligible patients were asked about their interest in participating in the study by trained researchers at the hospital during regular consultations for cancer treatment. After verbal acceptance and signing an informed consent form, they were directed to a reserved room to assess nutritional status (anthropometry) and muscle strength. Clinical data was obtained from the digital records at the hospital and included age, sex, ethnicity, primary tumor site, treatment performed and CT images.
**Anthropometric evaluation**

Three trained researchers measured body weight, height and CC. Body mass and height were determined by an electronic scale (Filizola®), with a precision of 100g. Body Mass Index (BMI) was calculated as a ratio of weight (kg) and height squared (m²), using the cut-off points proposed by the WHO: underweight (< 18.5 kg/m²), normal weight (18.5 to 24.9 kg/m²), overweight (25 to 29.9 kg/m²) and obese (≥ 30 kg/m²) [19]. For CC measurement, individuals were seated with the legs positioned at a 90˚ angle with the thigh and the inelastic band (Sanny®) around the maximum calf muscle circumference (in both legs). The measurement was performed in triplicate, and the maximum value was used. Low CC was classified using the cutoff points purposed by Barbosa-Silva et al.: 34 cm for men and 33 cm for women [20].

**Muscle strength assessment**

Handgrip strength (HGS, kg) of both arms was measured using a hydraulic dynamometer (Jamar®). Patients were instructed to adjust the dynamometer and tighten it by producing as much force as possible [21]. Three attempts were made in each hand alternately, with a minimum rest period of 60 seconds for each hand [22]. The highest value recorded was used as maximum muscle strength [23]. Low HGS was determined based on the reference values of the EWGSOP2, for diagnostic of sarcopenia (HGS < 27kg and < 16kg for male and female, respectively) [15].

**Muscle mass assessment**

Skeletal MM analysis was performed by evaluating using CT scans at the level of third lumbar vertebra (L3), using the Slice-O-Matic version 5.0 program (Tomovision, Montreal, Canada). A single trained researcher with anatomical knowledge selected and analyzed specific tissue using Hounsfield Unit (HU) boundaries of -29 to +150 for the skeletal muscle area (SMA, including psoas, erector spinae, lumbar square, transverse abdominal, internal and external oblique, rectus abdominis) [24]. Skeletal Muscle Index (SMI) was calculated by the total cross-sectional area (cm²) divided by height squared (m²). The SMI cut-off point proposed by Caan et al. was used to define low SMI, used as a marker of muscle quantity for the diagnostic of sarcopenia: < 52.3 cm²/m² for men and < 37.6 cm²/m² for women with a BMI < 30 kg/m² and < 54.3 cm²/m² for men and < 46.6 cm²/m² for women with BMI > 30 kg/m² [25]. Muscle quality was assessed through skeletal muscle radiodensity (SMD) from CT images and compared to the cut-off points by Kroenke et al.: < 35.5 HU and < 32.5 HU for males and females, respectively [26].

**Definition of sarcopenia**

Individuals with sarcopenia were classified by two different criteria, according to the EWGSOP2; a) low HGS + reduced MM assessed by CT (including low MM quality and/or quantity, named “sarcopenia by low MM”; and b) low HGS + low CC, named “sarcopenia by low CC” [15].

**Statistical analysis**

Data analysis was performed in SPSS version 22.0 for Windows. The Kolmogorov-Smirnov test was performed to assess the normality of the data. Categorical variables are expressed as absolute and relative frequency, and numerical data as mean and standard deviation. Differences in general characteristics between the sex of the patients were evaluated using the Chi-square test or Fisher’s exact test for categorical variables. Differences between the quantitative
variables in patients classified with sarcopenia according to the different criteria were evaluated using independent t-test. Pearson’s correlation test was performed to verify the correlation between CC and MM by CT (SMI). The Kappa coefficient between low CC and low SMI was calculated and, for its classification, the reference values considered were: < 0.20 as poor, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, 0.81–0.99 as almost perfect, and 1.00 as perfect [27]. Sensitivity, specificity, positive and negative predictive values were calculated. A p value < 0.05 was considered statistically significant for all tests.

Results
A total of 208 patients were interviewed, but 21 were unable to have their CC assessed due to leg edema or amputation. After the interview, the CT image was inaccessible for analysis in 79 patients (CT exams were older than 30 days). Thus, 108 elderly cancer patients were considered eligible, with a mean age of 70.6 ± 7.4 years old. Table 1 shows the clinical variables of the sample. The sex distribution is nearly even, with a slight majority of females (52.3%). Regarding the disease characteristics, the most frequent type was of colorectal cancer, followed by gastric tumor (27.8% and 22.2%, respectively), and advanced stages (III and IV) were diagnosed in more than a half of the patients (54.6%). The majority of the evaluated patients have had previous treatment (74.1%). According to BMI categories, 47.2% of patients classified with normal BMI and 30.6% with overweight. Only the variables ethnicity and cancer site showed differences between sexes.

Based on the EWGSOP2 criteria using CT data (sarcopenia by low MM), the prevalence of sarcopenia was of 24.1% (26 of 108 patients). When using the EWGSOP2 criteria with CC (sarcopenia by low CC), the prevalence was of 25.9% (28 of 108 patients). The overlap was observed in 21 individuals classified by both definitions of sarcopenia (Fig 1).

The prevalence of low CC, low HGS, and low MM (by SMI measure) were observed in 46.3%, 39.8%, and 24.1%, respectively. Table 2 presents the frequency of sarcopenia and related variables between the different criteria used. All variables presented differences between patients classified with and without sarcopenia regardless of the method used for classification. Patients with sarcopenia showed lower BMI, CC, SMA, SMI, SMD, and HGS.

The correlation between measures of CC and skeletal MM measured by CT and adjusted by height (SMI) in the sample and according to sex is presented in Fig 2. CC was weak positively correlated with SMI in the sample (r = 0.3431, p < 0.001) and in females (r = 0.3001, p = 0.023), and moderate in males (r = 0.4573, p < 0.001). Nevertheless, stronger and statistically significant correlations were observed between CC and the total MM (without dividing by height squared) analyzed by CT images. The correlations for the total sample, males and females, were r = 0.4078, r = 0.6492, and r = 0.4611, respectively (all p-value <0.001). Therefore, CC is considered a good indicator of MM. Analysis of correlation between CC and SMD were performed and showed no correlation (r = -0.02624, p = 0.7875; r = -0.1371, p = 0.373; r = 0.01385, p = 0.9185 for the general sample, males and females, respectively).

The agreement between the sarcopenia diagnostic criteria (using CT or CC for MM evaluation) is observed in Table 3. The sensitivity, specificity, and accuracy were calculated according to sex. For the total sample was observed 81% sensitivity, and 92% specificity, with higher values in females (86% sensitivity, and 91% specificity) compared to males (75% sensitivity, and 92% specificity). The Kappa tests present similar results, with a substantial agreement for females (K = 0.729) and males (K = 0.673).

Discussion
The main finding of the present study points out that CC can be used, with good accuracy, as a MM marker to diagnose sarcopenia in elderly patients with cancer. CC is a relatively quick,
cost-effective, and easy measurement that can help to identify sarcopenia without the need for sophisticated and expensive techniques. To the best of our knowledge, this is a pioneer study evaluating the accuracy of sarcopenia-based CC, compared to CT images, in this population. Previously, Velazquez-Alva et al. conducted a cross-sectional study to compare the prevalence of sarcopenia according to EWGSOP using SMI and CC in 137 Mexican elderly women [14, 28]. However, the population was composed only of women without cancer, and the diagnostic algorithm used in the study was that of the previous version published in 2010, not yet reviewed [14].

Low skeletal MM is highly prevalent in older patients with cancer and affects 5% to 89% of them depending on the type and stage of cancer [29]. The prevalence of sarcopenia in the present study is quite similar to other previous recent ones, reporting 21.2% to 48.2%, but it is important to note that the criteria to define sarcopenia used by the studies are different, being the majority only by CT images [30–34]. A recent study found a similar prevalence of

Table 1. General characteristics of cancer patients according to sex.

| Variables          | Total (n = 108) | Male (n = 51) | Female (n = 57) | p-value |
|--------------------|-----------------|---------------|-----------------|---------|
| Age                |                 |               |                 |         |
| 60–69 years        | 51 (47.2%)      | 19 (37.3%)    | 32 (56.1%)      | 0.050   |
| ≥70 years          | 57 (52.8%)      | 32 (62.7%)    | 25 (43.9%)      |         |
| Ethnicity          |                 |               |                 | 0.002   |
| Caucasian          | 40 (37.0%)      | 11 (21.6%)    | 29 (50.9%)      |         |
| Non-caucasian      | 68 (63.0%)      | 40 (78.4%)    | 28 (49.1%)      |         |
| Cancer site        |                 |               |                 | < 0.001 |
| Head and neck      | 7 (6.5%)        | 5 (9.8%)      | 2 (3.5%)        |         |
| Gastric            | 24 (22.2%)      | 15 (29.4%)    | 9 (15.8%)       |         |
| Colon and rectum   | 30 (27.8%)      | 14 (27.5%)    | 16 (28.1%)      |         |
| Breast             | 15 (13.9%)      | -             | 15 (26.3%)      |         |
| Prostate           | 14 (13.0%)      | 14 (27.5%)    | -               |         |
| Other              | 18 (16.7%)      | 3 (5.9%)      | 15 (26.3%)      |         |
| Staging of disease |                 |               |                 | 0.078   |
| I-II               | 30 (27.8%)      | 9 (17.6%)     | 21 (36.8%)      |         |
| III-IV             | 59 (54.6%)      | 31 (60.8%)    | 28 (49.1%)      |         |
| Unknown            | 19 (17.6%)      | 11 (21.6%)    | 8 (14.0%)       |         |
| Previous Treatment |                 |               |                 | 0.097   |
| Yes                | 80 (74.1%)      | 34 (66.7%)    | 46 (80.7%)      |         |
| No                 | 28 (25.9%)      | 17 (33.3%)    | 11 (19.3%)      |         |
| Nutritional status |                 |               |                 | 0.620   |
| (BMI)              |                 |               |                 |         |
| Underweight        | 9 (8.3%)        | 5 (9.8%)      | 4 (7.0%)        |         |
| Normal             | 51 (47.2%)      | 26 (51.0%)    | 25 (43.90%)     |         |
| Overweight         | 33 (30.6%)      | 15 (29.4%)    | 18 (31.6%)      |         |
| Obese              | 15 (13.9%)      | 5 (9.8%)      | 10 (17.5%)      |         |

Data in absolute (n) and relative (%) frequency; p value with Chi-square test and Fisher’s exact test.

1Previous treatment including chemotherapy, radiotherapy, surgery alone or combined.

2BMI below 18.5 kg/m².

3BMI 18.5–24.9 kg/m².

4BMI 25.0–29.9 kg/m².

5BMI 30 kg/m² and above.

BMI, Body Mass Index.

https://doi.org/10.1371/journal.pone.0257446.t001
sarcopenic (27.1%) in 439 older patients with cancer (60–95 years; 43.5% women), using the same diagnostic criteria of the present study (EWGSOP2) [35]. Another important issue is that most patients of the present study had advanced cancer and had already undergone some type of treatment that can accelerate declines in MM. Williams et al., evaluating older adults before and after cancer diagnosis, observed that after cancer diagnosis, there was a decline in MM, but not in HGS or gait speed, and these declines were more striking in patients with metastases [36].

To our knowledge, few studies available in the literature have used CC as an indicator of MM in cancer patients. Our research group recently showed that low CC can predict the risk of mortality in a cohort of 250 patients with cancer [37]. Patients with low CC have a risk of death three times higher than patients with normal CC, even after adjustment for confounders; low SMI was significantly associated with mortality in crude analysis, but not after adjustment for age, sex, and stage of disease [37]. These findings reinforce the use of CC as a simple, easy,

![Fig 1. Concordance of individual cases identified by European Working Group on Sarcopenia in Older People 2 (EWGSOP2) considering muscle mass (MM) evaluated by computed tomography (sarcopenia by low MM) and by calf circumference (CC) (sarcopenia by low CC).](https://doi.org/10.1371/journal.pone.0257446.g001)

Table 2. Frequency of sarcopenia and comparison of quantitative variables in patients classified with sarcopenia according to the different criteria (n = 108).

|                        | Sarcopenia by low MM | Sarcopenia by low CC |
|------------------------|----------------------|----------------------|
| **No**                 | **Yes**              | **No**               | **Yes**              |
| **(82; 75.9%)**        | **(26; 24.1%)**      | **(80; 74.1%)**      | **(28; 25.9%)**      |
| Age (years)            | 69.2 ± 7.6           | 74.9 ± 5.2           | <0.001               | 69.7 ± 7.7           | 73.2 ± 6.3 | 0.033 |
| Weight (Kg)            | 64.1 ± 12.2          | 54.4 ± 11.9          | 0.001                | 65.8 ± 11.7          | 50.4 ± 8.2 | <0.001 |
| BMI (kg/m²)            | 25.6 ± 4.4           | 22.6 ± 4.3           | 0.003                | 26.0 ± 4.3           | 21.7 ± 3.7 | <0.001 |
| CC (cm)                | 34.2 ± 3.4           | 30.6 ± 2.6           | <0.001               | 34.6 ± 3.2           | 29.8 ± 1.9 | <0.001 |
| SMA (cm²)              | 126.0 ± 30.7         | 108.3 ± 23.0         | 0.008                | 127.4 ± 30.6         | 105.8 ± 21.1 | <0.001 |
| SMI (cm²/m²)           | 49.9 ± 9.2           | 44.9 ± 7.9           | 0.015                | 49.9 ± 9.4           | 45.2 ± 7.1 | <0.001 |
| SMD (HU)               | 40.5 ± 8.9           | 34.2 ± 8.6           | 0.002                | 39.6 ± 9.8           | 37.3 ± 7.2 | 0.008 |
| HGS (kg/F)             | 24.8 ± 9.8           | 13.8 ± 6.1           | <0.001               | 25.3 ± 9.3           | 13.1 ± 6.4 | <0.001 |

p-value with independent-t test comparing patients with and without sarcopenia.

1Low MM according to Cana et al. [25].

2Low CC according to Barbosa-Silva et al. [20].

BMI, Body Mass Index; CC, Calf Circumference; SMA, Skeletal Muscle Area; SMI, Skeletal Muscle Index; SMD, Skeletal Muscle Radiodensity; HU, Hounsfield Unit; HGS, Handgrip Strength.

https://doi.org/10.1371/journal.pone.0257446.t002
Comparison of sarcopenia in cancer patients using different parameters of muscle mass

A

Skeletal Muscle Index (cm²/m²)

Calf Circumference (cm)

r = 0.3431, p < 0.001

B

Skeletal Muscle Index (cm²/m²)

Calf Circumference (cm)

r = 0.4573, p < 0.001

C

Skeletal Muscle Index (cm²/m²)

Calf Circumference (cm)

r = 0.3001, p = 0.023
cost-effective anthropometric measurement for assessing MM and screening patients with cancer.

Other studies have compared different MM indicators, including CC, for the diagnosis of sarcopenia and malnutrition in cancer patients. SARC-F is a simple and easy tool for screening sarcopenia, based on a 5-item questionnaire that measures strength, assistance in walking, rising from a chair, climbing stairs, and falls [38]. However, a major problem of SARC-F is its low sensitivity. Researches from Brazil developed an enhanced version of SARC-F (SARC-CalF) by incorporating CC into the SARC-F, which could significantly increase its sensitivity and overall diagnostic accuracy in community-dwelling older populations [39]. Because of the grown interest in this tool, other researchers also verified that SARC-CalF have better diagnostic performance as compared to the original questionnaire in the same population [40–42]. Similar results also were observed in cancer patients, when it was compared SARC-F with SARC-CalF for screening sarcopenia in 309 advanced cancer patients [43].

Recently, the Global Leadership Initiative on Malnutrition (GLIM) criteria was proposed to identify malnutrition in adults in a clinical setting [44]. With the aim to evaluate malnutrition according to the GLIM criteria using different MM indices in lung cancer patients, Yin et al. [45] performed a multicenter, observational cohort study, and found that CC was effective for determining the nutritional status of patients, having the best performance in comparing with other anthropometric methods. In fact, other studies also showed the fair performance of CC for identifying low MM in cancer patients, and its good performance to predict mortality [37, 46, 47]. In non-cancer patients, CC was also positively correlated with skeletal MM, and it could be used as a surrogate marker of MM for diagnosing sarcopenia [20, 48].

Nowadays, there is an increase in the number of reports on body composition assessment in patients with cancer for the diagnostic of sarcopenia. The definition of sarcopenia as a state of severe depletion of skeletal MM (SMI), known as secondary sarcopenia, has been largely established for cancer patients using CT measures and defined based on the risk of mortality [49–51]. Other measures of body composition have been used in cancer patients, including dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance (BIA) [52]. Although the use of the algorithm EWGSOP2 for the diagnosis of sarcopenia in the elderly is well established for this population, researchers are not yet unanimous about the use of this reference to define sarcopenia in patients with cancer. The use of different sarcopenia criteria for cancer patients makes it difficult to compare studies, and it is suggested that this criterion should be standardized to better understand this phenomenon.

Table 3. Accuracy test for sensitivity and specificity between different methods for low muscle mass assessment, using EWGSOP2 sarcopenia criteria in cancer patients.

|                      | Total (n = 108) | Male (n = 51) | Female (n = 57) |
|----------------------|----------------|--------------|-----------------|
| Kappa (p-value)      | 0.704 (p < 0.001) | 0.673 (p < 0.001) | 0.729 (p < 0.001) |
| Accuracy (%)         | 88.9            | 88.2         | 89.5            |
| Prevalence (%)       | 25.9            | 23.5         | 28.1            |
| Sensitivity (%)      | 80.8            | 75.0         | 85.7            |
| Specificity (%)      | 91.5            | 92.3         | 90.7            |
| Positive predictive value (%) | 75.0            | 75.0         | 75.0            |
| Negative predictive value (%) | 93.8            | 92.3         | 95.1            |

https://doi.org/10.1371/journal.pone.0257446.t003
The cutoffs of low MM and low SMD varied significantly across studies, and it can represent a limitation for the present study. As we do not have any reference values developed for the Brazilian population, we used those proposed by Caan et al. [25] from a sample of American patients with stage I–III invasive colorectal cancer, and it is possible that it may not have been adequate for our population (Latin-American patients with cancer). For low CC, the cutoffs used in this study came from a regional reference, validated against DXA in a sample representative for the local population [20]. Despite the limitations, the results are relevant demonstrating the practical applicability of CC measures for the diagnostic of sarcopenia in cancer patients.

In conclusion, the agreement of sarcopenia defined by EWGSOP2 using MM assessed by CC or CT images (SMI) was moderate, with high specificity and negative predictive value, suggesting that CC can be used as a MM indicator in cancer patients. Although the application of the EWGSOP2 in the definition of sarcopenia in older cancer patients is still not a consensus, it may indeed be advantageous in clinical settings, because the measurements used in the algorithm (low HGS associated with low CC) are easier to obtain than the analysis of MM by CT images.

Author Contributions

Conceptualization: Ana Paula Trussardi Fayh.
Data curation: Ana Paula Trussardi Fayh, Iasmin Matias de Sousa.
Formal analysis: Ana Paula Trussardi Fayh, Iasmin Matias de Sousa.
Investigation: Iasmin Matias de Sousa.
Methodology: Ana Paula Trussardi Fayh.
Project administration: Ana Paula Trussardi Fayh.
Supervision: Ana Paula Trussardi Fayh.
Writing – original draft: Ana Paula Trussardi Fayh, Iasmin Matias de Sousa.
Writing – review & editing: Ana Paula Trussardi Fayh, Iasmin Matias de Sousa.

References

1. World Health Organization. Ageing and health. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
2. Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores Sociais: Uma Análise Das Condições de Vida Da População Brasileira. (IBGE, ed.). Rio de Janeiro: IBGE; 2018.
3. IARC. International Agency for Research on Cancer. Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018. Geneva; 2018.
4. Naeim A, Aapro M, Subbarao R, Baiducci L. Supportive care considerations for older adults with cancer. J Clin Oncol. 2014; 32: 2627–2634. https://doi.org/10.1200/JCO.2014.55.3065 PMID: 25071112
5. Ryan AM, Power DG, Daly L, Cusheen SJ, ÓBhualchaille E, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: The skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016; 75: 199–211. https://doi.org/10.1017/S0029665115000419X PMID: 26786393
6. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017; 36: 1187–1196. https://doi.org/10.1016/j.clnu.2017.06.017 PMID: 28689670
7. Broughman JR, Williams GR, Deal AM, Yu H, Nyrop KA, Alston SM, et al. Prevalence of sarcopenia in older patients with colorectal cancer. J Geriatr Oncol. 2015; 6: 442–445. https://doi.org/10.1016/j.jgo.2015.08.005 PMID: 26365898
8. Given B, Given CW. Older Adults and Cancer Treatment. Cancer. 2008; 113: 3505–3511. https://doi.org/10.1002/cncr.23939 PMID: 19058145
9. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: Impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013; 4: 95–109. https://doi.org/10.1007/s13539-012-0087-1 PMID: 23097000

10. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127: 990S–991S. https://doi.org/10.1093/jn/127.5.990S PMID: 9164280

11. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: A Time for Action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019; 10: 956–961. https://doi.org/10.1002/jcsm.12483 PMID: 31523937

12. Xiao J, Caan BJ, Feliciano EMC, Meyerhardt JA, Peng PD, Baracoss VE, et al. Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery. JAMA Surg. 2020; 12:e202497. https://doi.org/10.1001/jamasurg.2020.2497 PMID: 32805015

13. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489–495. https://doi.org/10.1016/S1470-2045(10)70218-7 PMID: 21296615

14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48: 16–31. https://doi.org/10.1093/ageing/afy169 PMID: 30312306

15. Aubrey J, Esfandiari N, Baracoss VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014; 210: 489–497. https://doi.org/10.1111/apha.12224 PMID: 24393306

16. Prado CMM, Heymsfield SB. Lean Tissue Imaging: A New Era for Nutritional Assessment and Intervention. J Parenter Enter Nutr. 2014; 38: 940–953; https://doi.org/10.1177/0148607114550189 PMID: 25239112

17. Daly LE, Prado CM, Ryan AM. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018; 77: 135–151. https://doi.org/10.1017/S0029665118000046 PMID: 29745361

18. World Health Organization. Obesity and overweight. 2014. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/

19. Boadella JM, Kuijer PP, Sluiter JK, Frings-Dresen MH. Effect of self selected handgrip position on maximal handgrip strength. Arch Phys Med Rehabil. 2005; 86: 328–331. https://doi.org/10.1016/j.apmr.2004.05.003 PMID: 15706562

20. McCregor RA, Cameron-Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan. 2014; 3: 3–8. https://doi.org/10.1186/2046-2395-3-3 PMID: 24588808

21. Addison O, Marcus RL, LaStayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol. 2014; e309570. https://doi.org/10.1155/2014/309570 PMID: 24527032

22. Mourtzakis M, Prado CMM, Liefers JR, Reiman T, McCargar LJ, Baracoss VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33: 997–1006. https://doi.org/10.1139/H08-075 PMID: 18923576

23. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiol Biomarkers Prev. 2017; 26: 1008–1015. https://doi.org/10.1158/1055-9965.EPI-17-0200 PMID: 28506965

24. Kroenke CH, Prado CM, Meyerhardt JA, Weltzien EK, Xiao J, Feliciano EMC, et al. Muscle radiodensity and mortality in patients with colorectal cancer. Cancer. 2018; 124: 3008–3015. https://doi.org/10.1002/cncr.31405 PMID: 29797673

25. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data. Biometrics. 1977; 33: 159–174. https://doi.org/10.2307/2529310 PMID: 843571

26. Velazquez-Alva MC, Irioyen Camacho ME, Lazarevich I, Delgadillo Velazquez J, Acosta Dominguez P, Zepeda Zepeda MA. Comparison of the prevalence of sarcopenia using skeletal muscle mass index
and calf circumference applying the European consensus definition in elderly Mexican women. Geriatr Gerontol Int. 2017; 17: 161–170. https://doi.org/10.1111/ggi.12652 PMID: 26534889

29. Looijaaard SLM, Heekert ML, Westh RC, Otten RHJ, Meskers CGM, Maier AB. Pathophysiological mechanisms explaining poor clinical outcome of older cancer patients with low skeletal muscle mass. Acta Physiol. 2020; e13516. https://doi.org/10.1111/apha.13516 PMID: 32478875

30. Brit NC, de Bree MEVR. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Oto-Rhino-Laryngoloy 2019; 276: 1475–1486. https://doi.org/10.1007/s00405-019-05361-4 PMID: 30830300

31. Xie H, Gong Y, Kuan J, Yan L, Ruan G, Tang S et al. Computed Tomography–Determined Sarcopenia Is a Useful Imaging Biomarker for Predicting Postoperative Outcomes in Elderly Colorectal Cancer Patients. Cancer Res Treat. 2020; 52: 957–972. https://doi.org/10.4143/crt.2019.695 PMID: 32311863

32. Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2016; 19: 986–993. https://doi.org/10.1007/s10120-015-0546-4 PMID: 26407875

33. Lee JS, Kim YS, Kim EY, Jin W. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer. Plos One. 2018; 13: e0202700. https://doi.org/10.1371/journal.pone.0202700 PMID: 30125312

34. Kawaguchi Y, Hanoaka J, Otshio Y, Okamoto K, Kaku R, Hayashi K. Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer. Gen Thorac Cardiovasc Surg. 2019; 67: 949–954. https://doi.org/10.1007/s11748-019-01125-3 PMID: 30972530

35. Otten L, Stobås N, Franz K, Otten L, Stobås N, Franz K, et al. Impact of sarcopenia on 1-year mortality in older patients with cancer. Age Ageing. 2019; 48: 413–418. https://doi.org/10.1093/ageing/afy212 PMID: 30608508

36. Williams GR, Chen Y, Shachar SS, Klepin AM, et al. Impact of sarcopenia on 1-year mortality in older patients with cancer. J Am Med Dir Assoc. 2016; 17: 1136–1141. https://doi.org/10.1016/j.jamda.2016.08.004 PMID: 27066316

37. Sousa IM, Bielemann RM, Gonzalez MC, Rocha IMG, Barbalho ER, Carvalho ALM, et al. Low calf circumference is an independent predictor of mortality in cancer patients: a prospective cohort study. Nutrition. 2020: 78–80. https://doi.org/10.1016/j.nut.2020.110816 PMID: 32569952

38. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7: 28–36. https://doi.org/10.1002/jcsm.12048 PMID: 27066316

39. Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK, Gonzalez MC, Grupo de Estudos em Composiçã o Corporal e Nutrição (COCONUT). Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016; 17: 1136–1141. https://doi.org/10.1016/j.jamda.2016.08.004 PMID: 27066316

40. Yang M, Hu X, Xie L, et al. Screening sarcopenia in community-dwelling older adults: SARC-F vs SARC-F combined with calf circumference (SARC-CalF). J Am Med Dir Assoc. 2018; 19: 277.e1–277.e8. https://doi.org/10.1016/j.jamda.2017.12.016 PMID: 29477774

41. Krzymińska-Siemaszko R, Deskur-Śmielecka E, Kalużniak-Szymanowska A, Lewandowicz M, Wieczorewska-Tobis K. Comparison of Diagnostic Performance of SARC-F and Its Two Modified Versions (SARC-CalF and SARC-F-EBM) in Community-Dwelling Older Adults from Poland. J Interv Aging. 2020; 15: 583–594. https://doi.org/10.1002/jia2.250508 PMID: 32425513

42. Mo Y, Dong X, Wang XH. Screening accuracy of SARC-F combined with calf circumference for sarcopenia in older adults: a diagnostic meta-analysis. J Am Med Dir Assoc. 2020; 21: 288–289. https://doi.org/10.1016/j.jamda.2019.09.002 PMID: 31672568

43. Fu X, Tian Z, Thapa S, Sun H, Wen S, Xiong H. Comparing SARC-F with SARC-CalF for screening sarcopenia in advanced cancer patients. Cmfnutrit. 2020; S0261-5614(20):30083–2. https://doi.org/10.1016/j.clinu.2020.02.020 PMID: 32143888

44. Cederholm T, Jensen GL, Corneja MTD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM Criteria for the Diagnosis of Malnutrition—A Consensus Report From the Global Clinical Nutrition Community. J Cachexia Sarcopenia Muscle. 2018; 10: 207–217. https://doi.org/10.1002/jcsm.12938 PMID: 30920778

45. Yin L, Lin X, Li N, Zhang M, He X, Liu J, et al. Evaluation of the Global Leadership Initiative on Malnutrition Criteria Using Different Muscle Mass Indices for Diagnosing Malnutrition and Predicting Survival in Lung Cancer Patients. J Parenter Enter Nutr. 2020 May 9. 2020 May 9. https://doi.org/10.1002/jpen.1873 Epub ahead of print. PMID: 32386328

46. Souza NC, Gonzalez MC, Martucci RB, Rodrigues VD, Pinho NB, Qureshi AR, et al. Comparative Analysis Between Computed Tomography and Surrogate Methods to Detect Low Muscle Mass
Colorectal Cancer Patients. J. Parenter. Enter. Nutr. 2019 Nov 17. https://doi.org/10.1002/jpen.1741 Epub ahead of print. PMID: 31736112

47. Wiegert EVM, de Oliveira LC, Lima LC, Calixto-Lima L, Borges NA, Rodrigues J, et al. Association between low muscle mass and survival in incurable cancer patients: A systematic review. Nutrition. 2020; 72:110695. https://doi.org/10.1016/j.nut.2019.110695 PMID: 32007806

48. Kawakami R, Murakami H, Sanada K, Tanaka N, Sawada SS, Tabata I, et al. Calf circumference as a surrogate marker of muscle mass for diagnosing sarcopenia in Japanese men and women. Geriatr. Gerontol. Int. 2015; 15: 969–976. https://doi.org/10.1111/ggi.12377 PMID: 25243821

49. Weinberg MS, Shachar SS, Muss HB, Deal AM, Popuri K, Yu H, et al. Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J. 2018; 24: 278–284. https://doi.org/10.1111/tbj.12952 PMID: 29139618

50. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 2018; 4: 1–18. https://doi.org/10.1038/s41572-018-0001-z PMID: 29930242

51. Martin L, Gioulbasanis I, Senesse P, Baracos VE. Cancer-Associated Malnutrition and CT-Defined Sarcopenia and Myosteatosis Are Endemic in Overweight and Obese Patients. J. Parenter. Enter. Nutr. 2019; 0: 1–10. https://doi.org/10.1002/jpen.1597 PMID: 31012128

52. Boshier PR, Heneghan R, Markar SR, Baracos VE, Low DE. Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis. Dis. Esophagus. 2018; 31: 1–11. https://doi.org/10.1093/dote/doy047 PMID: 29846548